(UroToday.com) The European Society of Medical Oncology (ESMO) 2021 virtual annual meeting’s non-prostate cancer session included a presentation by Dr. Toni Choueiri discussing outcomes of subgroup analyses and a toxicity update among patients in the phase 3 CLEAR trial for advanced renal cell carcinoma (RCC). In the CLEAR trial, lenvatinib + pembrolizumab demonstrated significant improvement in PFS (24 months versus 9 months; HR 0.39, 95% CI 0.32-0.49), OS (not reached in either arm; HR 0.66, 95% CI 0.49-0.88), and ORR (71% versus 36%; OR 4.35, 95% CI 3.16-5.97) versus sunitinib for patients with advanced RCC. The analysis reported at the 2021 ESMO virtual congress explored efficacy outcomes in patients with or without adverse pathologic features (ie. sarcomatoid histology, bone metastases, liver metastases, and no prior nephrectomy) in the lenvatinib + pembrolizumab versus sunitinib arms. Additionally, the number of patients who received high-dose corticosteroids to manage immune-related adverse events is reported.